



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/10, 47/36, 47/38	A1	(11) International Publication Number: WO 95/17166 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/US94/14480 (22) International Filing Date: 16 December 1994 (16.12.94) (30) Priority Data: 170,941 20 December 1993 (20.12.93) US (60) Parent Application or Grant (63) Related by Continuation US 170,941 (CON) Filed on 20 December 1993 (20.12.93) (71) Applicant (for all designated States except US): CALGON VESTAL LABORATORIES, INC. [US/US]; 7501 Page Avenue, St. Louis, MO 63133 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CORNELL, Marc, D. [US/US]; 7501 Page Avenue, St. Louis, MO 63133 (US). KAISER, Nancy, E. [US/US]; 7501 Page Avenue, St. Louis, MO 63133 (US). BRENDEN, Rita, A. [US/US]; 7501 Page Avenue, St. Louis, MO 63133 (US). (74) Agent: MERCK & CO., INC.; Patent Department, 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>
(54) Title: WOUND HYDRATING GEL WITH NOVEL PRESERVATIVE SYSTEM AND LOW CYTOTOXICITY		
(57) Abstract <p>The present invention relates to a preserved, yet non-cytotoxic alginate based hydrating gel system for the purpose of treating wounds that need moisture. Sodium carboxymethylcellulose and an alginate polymer blend impart sufficient viscosity to an aqueous solution to provide moisture to the wound. The blend reduces the cytotoxicity of a combination of preservatives incorporated into the system. More specifically, the invention relates to a wound hydrating gel comprising a) a hydrocolloid mixture of carboxymethylcellulose and sodium/calcium alginate, and b) a preservative system. This invention further relates to methods of preparing and using the wound hydrating gel.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

TITLE OF THE INVENTION

WOUND HYDRATING GEL WITH NOVEL PRESERVATIVE
5 SYSTEM AND LOW CYTOTOXICITY

BACKGROUND OF THE INVENTION

It is well known that the healing of normal wounds is significantly enhanced by providing a moist environment for the wound
10 during healing. Material dressing design for wound repair is largely based on the control of local hydration and oxygen tension.

The ability of a dressing to transmit moisture vapor from a wound bed to the external atmosphere is referred to as occlusion. It characterizes the relative permeability of that dressing to gases.
15 Occlusion influences both epidermal resurfacing and dermal repair.

Exposed wounds are more inflamed, painful, itchy, and have thicker crusts than moist wounds during the inflammatory stage of healing. Collagen production is greater in the dermis of occluded wounds when compared to the dermis of air-exposed wounds. Furthermore, the
20 dermis of superficial wounds exposed to the air is more fibroplastic, fibrotic, and scarred than the dermal component of a similar wound maintained in a moist environment. Epidermal cells migrate only over viable tissues as they require a blood and nutritional supply that is adequate to their energy needs. Because the migrating "tongue" of
25 epithelium must burrow between any eschar (crust or scab) and the underlying tissue, the presence of this dry crust impedes wound healing. Thus, if the wound is kept moist and is protected from the external environment so that desiccation and crust formation is prevented, wound healing will occur at a more rapid pace.

30 Currently, the products available on the market to add moisture to the wound environment are either sterile, e.g., IntraSite™ Gel (commercially available from Smith & Nephew United, Inc., Quebec, Canada), or multi-component formulations containing, among other things, preservatives, e.g. Carrington Laboratories Dermal Wound Gel and Dressing™ (commercially available from Carrington Laboratories,

- 2 -

Irvington, TX) and Biolex™ Wound Gel (commercially available from Catalina Biomedical Corporation, Duarte, CA).

5 IntraSite™ Gel is composed of water, propylene glycol, and a starch co-polymer. IntraSite™ Gel is sterilized using radiation prior to packing in foil packages, and therefore no preservatives are required. However, exposure of gels to radiation causes loss of viscosity due to rupture of cross links and depolymerization of polymer chain, all of
10 which can possibly change color, odor, and clarity.

 Other commercially available gels contain preservatives and do not require radiation sterilization. Preservatives, however, are cytotoxic, and additional ingredients are used to mitigate the effect.

 Carrington's Dermal Wound Gel™ comprises three
15 preservatives: sodium benzoate, potassium sorbate, and imidazolidinyl urea. The remaining components are purified water, povidone, panthenol, carbomer 940, triethanolamine, allantoin, glutamic acid, NaCl, methylparaben (also a preservative), acemannan hydrogel, citric acid and sodium metabisulfite. NaCl, allantoin, povidone, and panthenol most
20 likely act to counter the cytotoxic effect of the preservatives.

 Catalina's Biolex™ Wound Gel also comprises three preservatives: methyl/propyl paraben, K sorbate, and Diazolanal. Allantoin and panthenol are present and most likely act as cytotoxicity reducing agents.

25 The present invention is a non-cytotoxic wound hydrating gel which delivers water to a wound by means of an alginate based hydrating gel containing a preservative system comprised of potassium sorbate, boric acid, and DMDM hydantoin.

30 SUMMARY OF THE INVENTION

 The present invention relates to a preserved, yet non-cytotoxic alginate based hydrating gel system for the purpose of treating wounds that need moisture. A hydrocolloid mixture of sodium carboxymethylcellulose and an alginate polymer blend impart sufficient viscosity to an aqueous solution to provide moisture to the wound. The

- 3 -

5 mixture reduces the cytotoxicity of a combination of preservatives incorporated into the system. More specifically, the invention relates to a non-cytotoxic wound hydrating gel comprising a) a hydrocolloid mixture of carboxymethylcellulose and sodium/calcium alginate, and b) a preservative system. This invention further relates to methods of preparing and using the non-cytotoxic wound hydrating gel.

10 DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a non-cytotoxic wound hydrating gel comprising a) a hydrocolloid mixture of sodium carboxymethyl-cellulose (CMC) and sodium/calcium alginate hydrocolloids, and optionally other hydrocolloids, and b) a preservative system. This invention further relates to methods of preparing and using said wound hydrating gel.

As used herein, the term "non-cytotoxic" refers to the characteristic of low cytotoxicity or no cytotoxicity (all or substantially all cells survive). The preferred sodium/calcium alginate hydrocolloid is a self gelling Na/Ca alginate having about 6-7% sodium minerals and about 2.5-3.5% calcium minerals (e.g., KELSET®, commercially available from Kelco, a division of Merck & Co., Inc.).

25 Preferably, CMC is present in an amount between about 0.1-1.0 wt. %, and Na/Ca alginate is present in an amount between about 0.2-2.00 wt. %. More preferably, CMC is present in an amount between about 0.2-0.8 wt. %, and Na/Ca alginate is present in an amount between about 0.5-1.5 wt. %. More preferably, CMC is present in an amount of about 0.6 wt. %, and Na/Ca alginate is present in an amount of about 1.5 wt. %.

30 Hydrocolloids which can optionally be used in addition to sodium/calcium alginate and CMC include Carbopol, including Carbopol 940, carrageenan, agar, and gelatin. The preservative system comprises dimethylol dimethylhydantoin (DMDM hydantoin) (commercially available from Lonza Chemical as Glydant 40-700, from McIntyre Chemical as Mackstat DM, and from Nipa Laboratories as Nipa Guard

- 4 -

DMDMH), an antimicrobial agent and a mold and yeast inhibitor. Preferably, the antimicrobial agent is boric acid and the mold and yeast inhibitor is potassium sorbate. The relative weight percentages of these components is about 0.05-0.1% dimethylol dimethylhydantoin, 0.1-0.3% antimicrobial agent, and from 0 to about 1.0% mold and yeast inhibitor. The remaining portion of the composition is comprised of deionized water.

10 The pH ranges from about 5.5 to about 7.0, preferably about 6.5.

 The composition of the present invention is prepared by adding deionized (DI) water to an appropriately sized vessel and initiating agitation, adding the potassium sorbate or other mold and yeast inhibitor, adding the dimethylol dimethylhydantoin, and adding the boric acid or other antimicrobial agent, adding the CMC slowly to the edge of the vortex and allowing the solution to mix for 60-90 minutes. The Na/Ca alginate powder is slowly added into the vortex of the solution and mixed into the solution for 60-90 minutes, or until product is uniform.

20 Once prepared, the wound hydrating gel is applied directly to the wound in order to "pack" the wound and provide a desirable healing environment, and may be conventionally delivered from a squeeze tube, a syringe or compressed air non-aerosol can, preferably by compressed air non-aerosol can.

25 The non-cytotoxic wound hydrating gel, which provides optimal environment for the moist wound healing process, is especially useful for management of pressure ulcers, stages I-IV, stasis ulcers, first and second degree burns, cuts, abrasions, skin tears and irritations of the skin.

30 In an exemplary application, a wound is cleansed with an appropriate non-cytotoxic solution such as SAF-Clens Chronic Wound Cleanser or Shur-Clens Skin Wound Cleansing Solution (both commercially available from Calgon Vestal Laboratories, St. Louis, MO) or with saline. A 1/8 to 1/4 inch layer of the wound hydrating gel is applied to cover the entire wound. The layer is covered with an

- 5 -

appropriate secondary dressing, such as gauze or other bandage. If gauze is used, it should be pre-moistened with saline or other appropriate noncytotoxic solutions. The gel is preferably changed daily or when the wound begins to dry.

The cytotoxicity of the present invention and those hydrating gels already on the market were determined using the Insert Cytotoxicity Assay described below.

10

Insert Cytotoxicity Assay - Part A: Gelatin Coating Millipore Inserts

Two hundred mls of sterile distilled water were added to a 300 ml beaker and heated until boiling. One hundred mgs of gelatin was then added and the solution mixed until the gelatin was completely dissolved. One ml of the still hot gelatin solution was then added to each millipore insert sitting upright in an individual well of a 6 well plate. The plates are then placed in a 50°C oven with the lids slightly ajar overnight or until dry. The gelatin coated inserts are then stored in the refrigerator at 4° C for use in Part B.

20

Insert Cytotoxicity Assay-Part B: Millipore Inserts Direct Contact Test

From a confluent flask of commercially available L929 mouse fibroblast cells, media was aspirated from the monolayer and the monolayer washed with 10 ml of modified Hanks Balanced Salts Solution (without calcium and magnesium with phenol red ("HBSS", Whittaker Bioproducts)). The media was again aspirated and 10 ml of Trypsin was added. Following incubation for 10 minutes at 37°C, the monolayer was gently dislodged and 10 ml of growth media (10X EMEM (10%), 200mm Glutamine (1%), Fetal Bovine Serum (5%), Omni Serum (5%), 7.5% NaHCO₃ (2%), Sterile distilled water (77%), commercially available from Whittaker Bioproducts) was added to quench the Trypsin. After mixing the solution was aliquoted into a large 50 milliliter centrifuge tube and centrifuged at 1000 rpm for 10 minutes with no brake. The supernatant was aspirated and the cells resuspended with a vortex in 2-10 mls of growth media, depending on the size of the

- 6 -

cell pellet. The exact amount of media added is not critical. The cells are then counted via the cell counting procedure described below.

5 Cell counting procedure: Suspend the cells as completely and evenly as possible. In a 13 x 100 mm plastic tube, combine 0.5 ml Trypan blue stain, 0.3 ml HBSS, and 0.2 ml cell suspension. Allow to stand at room temperature for 10 minutes. Fill both chambers of a Hemocytometer with the cell/dye suspension as follows: Place the
10 coverslip on the clean, dry hemocytometer and use a pasteur pipet to fill the chambers by capillary action. This is best done by touching the edge of the coverslip with the pasteur pipet. Place the hemocytometer under a microscope and focus until a gridwork is seen. The gridwork is the "chamber" for one side. The area that is 1/9th of the chamber is referred
15 to as a "square." Count the colorless cells (that have excluded the blue dye) in the squares indicated below, 5 squares per side of the hemocytometer. Calculate the average number of cells per square, multiply by the dilution factor (5) and multiply by 10^4 . This will give the number of cells per milliliter.

20 After counting the cells, dilute in growth media containing antibiotics (Penn/Strep fungizone, available from Whittaker Bioproducts, 1 ml per 100 ml of growth media) to a final concentration of 9×10^4 cells/ml. One ml of this cell suspension was then added to each gelatin coated millipore insert aseptically transferred from the 6-well plate in Part
25 A to a clean 6 well plate wherein, to each well, 6 mls of standard growth media was added outside of the insert and 3 mls to the inside of the insert. The plates were then incubated for 6 days at 37°C, 5% CO₂. After incubation, 2.5 mls or 2.5 gms of each sample of gel to be tested was distributed into a clean 6 well plate, 1 sample per well. 0.0050 gms of
30 sodium lauryl sulfate are add to a well containing a noncytotoxic control gel to make 0.10% SLS gel. Disks are aseptically removed from media and placed on top of the gel. 3 mls of growth media are then added to the top of each disk, which are then incubated at 37°C, 5% CO₂, for 4 hours.

The plates of inserts seeded 6 days prior are removed from the incubator. Inserts are aseptically removed from the sample. The disk is

- 7 -

placed in a clean 6 well plate. 2 mls of a standard fluorescein diacetate solution (prepared by dissolving 0.01 grams of powdered Fluorescein diacetate dye in 2 ml of acetone, then diluting the stock solution 1:250 in phosphate buffered saline) are added on top of the disk, and 2 mls outside of the disk. The disks were then refrigerated at 4° C for 20 minutes and read under an inverted fluorescent scope. Plates are viewed with bright field and fluorescent settings. Several fields are viewed per insert, and an average percentage of fluorescent cells (as compared to the number of cells visible under brightfield) is recorded.

A summary of the results of the assay comparing the present invention with the hydrating gels already on the market is given in the table following the examples. The following examples are illustrative only and are not intended to limit or restrict the present invention in any manner.

EXAMPLE 1

<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
DI Water	97.59	975.9
K Sorbate	0.2	2.0
DMDM Hydantoin	0.1	1.0
Boric Acid	--	--
CMC	0.6	6.0
KELSET®	1.5	15.0

pH: 6.5

Three aliquots of this batch were then assayed as described above.

- 8 -

EXAMPLE 2

5	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	97.55	975.5
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	--	--
	CMC	0.6	6.0
10	KELSET®	1.5	15.0

pH: 6.0

Three aliquots of this batch were then assayed as described above.

15

EXAMPLE 3

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	97.6	976.0
20	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	--	--
	CMC	0.6	6.0
	KELSET®	1.5	15.0

25 pH: 7.0 (unadjusted)

Three aliquots of this batch were then assayed as described above.

30

- 9 -

EXAMPLE 4

5	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	97.1	971.0
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.6	6.0
10	KELSET®	1.5	15.0

pH: 7.0

Three aliquots of this batch were then assayed as described above.

15

EXAMPLE 5

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	97.1	971.1
20	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.6	6.0
	KELSET®	1.5	15.0

25 pH: 6.5

Three aliquots of this batch were then assayed as described above.

30

- 10 -

EXAMPLE 6

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
5	DI Water	97.1	971.0
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.6	6.0
10	KELSET®	1.5	15.0

pH: 6.0

15 Three aliquots of this batch were then assayed as described above.

EXAMPLE 7

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
20	DI Water	87.1	871.0
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.6	6.0
	KELSET®	1.5	15.0
25	Propylene glycol	10.0	100.0

EXAMPLE 8

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
30	DI Water	87.1	871.0
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.6	6.0
	KELSET®	1.5	15.0
	Glycerin	10.0	100.0

- 11 -

EXAMPLE 9

5	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	87.46	874.6
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
10	Boric Acid	0.5	5.0
	CMC	0.04	0.4
	KELSET®	0.2	2.0
	Carbopol 940	0.75	7.5
	Propylene glycol	10.0	100.0
	Triethanolamine	0.75	7.5

15

EXAMPLE 10

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
	DI Water	87.0	870.0
20	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.1	1.0
	KELSET®	0.5	5.0
	Carbopol 940	0.5	5.0
25	Propylene glycol	10.0	100.0
	Triethanolamine	0.5	5.0

30

- 12 -

EXAMPLE 11

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
5	DI Water	97.25	972.5
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
10	CMC	0.2	2.0
	KELSET®	1.75	17.5

EXAMPLE 12

	<u>ITEM</u>	<u>WEIGHT %</u>	<u>WEIGHT(gms)</u>
15	DI Water	97.9	979.0
	K Sorbate	0.2	2.0
	DMDM Hydantoin	0.1	1.0
	Boric Acid	0.5	5.0
	CMC	0.8	8.0
20	KELSET®	0.5	5.0

25

30

- 13 -

Table
L929 mouse fibroblast cell viability ≥

5	<u>Product</u>	<u>% viable cells</u>		<u>% loss</u>
		<u>start</u>	<u>end</u>	
	control (saline, no gel)	100	95	5
	Carrington Laboratories	80	72	8
10	Dermal Wound Gel and Dressing™			
	"	100	90	10
	"	100	100	0
15	Biolex	100	10	90
	"	80	8	72
	1.5% Na./Ca alginate	100	90	10
20	"	100	90	10
	IntraSite™ Gel	100	95	5
	"	100	100	0
25	1.5% Na./Ca alginate with sodium lauryl sulfate	100	0	100

30

- 14 -

Table (continued)
L929 mouse fibroblast cell viability

	<u>Product</u>	<u>% viable cells</u>		<u>% loss</u>
		<u>start</u>	<u>end</u>	
5	KELSET [®] with sodium lauryl sulfate	100	0	100
10	KELSET [®]	100	80	20
	Example 1	100	85	15
	Example 2	100	93.3	6.7
15	Example 3	100	95	5
	Example 4	100	96.7	3.3
	Example 5	100	90	10
20	Example 6	100	93.3	6.7

For examples 1-6, % viable cells at end is represented as an average of three evaluated samples.

These tables clearly show that the non-cytotoxic wound hydrating gel of the present invention has an equivalent or superior toxicity profile as compared to the products currently available on the market. Furthermore, unlike the prior art, this low cytotoxicity is achieved without the addition of other ingredients to counter the toxicity of the preservatives located therein.

30

- 15 -

WHAT IS CLAIMED IS:

- 5 1. A non-cytotoxic wound hydrating gel comprising:
 - a. a hydrocolloid system comprising sodium/calcium alginate and sodium carboxymethylcellulose, and
 - 10 b. a preservative system.
2. The non-cytotoxic wound hydrating gel of Claim 1 wherein the sodium/calcium alginate is selected from a group of sodium/calcium alginates having about 6-7% sodium minerals and about
15 2.5-3.5% calcium minerals.
3. The non-cytotoxic wound hydrating gel of Claim 2 wherein CMC is present in an amount between about 0.1-1.0 wt. %, and Na/Ca alginate is present in an amount between about 0.2-2.00 wt. %.
20
4. The non-cytotoxic wound hydrating gel of Claim 3 wherein CMC is present in an amount of about 0.2-0.8 wt. %, and Na/Ca alginate is present in an amount of about 0.5-1.5 wt. %.
- 25 5. The non-cytotoxic wound hydrating gel of Claim 4 wherein CMC is present in an amount between about 0.6 wt. %, and Na/Ca alginate is present in an amount between about 1.5 wt. %
6. The non-cytotoxic wound hydrating gel of Claim 5
30 wherein the preservative system comprises:
 - a. dimethylol dimethylhydantoin,
 - b. an antimicrobial agent, and

- 16 -

c. a mold and yeast inhibitor.

5 7. The non-cytotoxic wound hydrating gel of Claim 6
 wherein:

a. the antimicrobial agent is boric acid, and

10 b. the mold and yeast inhibitor is potassium sorbate.

8. The non-cytotoxic wound hydrating gel of Claim 7
 wherein the relative weight percentages of the non-water components is
 about:

15	Na/Ca Alginate	1.5%
	DMDM Hydantoin	0.1%
	K Sorbate	0.2%
	Boric Acid	0.5%
20	CMC	0.6%.

9. A process for preparing the non-cytotoxic wound
hydrating gel of Claim 1 comprising the steps of:

25 a. dissolving, with agitation, all components of the
 preservative system in deionized water and thereafter maintaining the
 agitation;

30 b. adding sodium CMC to the edge the vortex and allowing
 the solution to mix for 60-90 minutes;

c. adding the Na/Ca alginate powder into the vortex of the
solution; and

d. mixing the solution until product is uniform.

- 17 -

10. A method of providing a moist wound environment to
5 facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 1.

11. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
10 the wound the non-cytotoxic hydrating gel of Claim 2.

12. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 3.

15 13. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 4.

20 14. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 5.

25 15. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 6.

30 16. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 7.

17. A method of providing a moist wound environment to
facilitate the healing process comprising the step of applying directly to
the wound the non-cytotoxic hydrating gel of Claim 8.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14480

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/10, 47/36, 47/38

US CL :424/488

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/488, 484; 252/315.3; 524/916; 514/944

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A 4,585,650 (NEWBERRY, JR.) 29 April 1986, Abstract, column 5, lines 5, 28-31.	1-17
Y	US, A, 5,192,802 (RENCER) 09 March 1993, Abstract, column 2, lines 22-31, column 3, lines 5, 28-31.	1-17
Y, P	US, A, 5,271,943 (BOGART) 21 December 1993, Title, column 6, line 18.	1-17

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 06 FEBRUARY 1995	Date of mailing of the international search report 06 APR 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Edward J. Webman</i> EDWARD J. WEBMAN
Facsimile No. (703) 305-3230	Telephone No. (703) 308-2351